Influence of body surface area on serum peak thyrotropin (TSH) levels after recombinant human TSH administration.
Recombinant human TSH (rhTSH) has been proposed as an alternative method to the withdrawal of thyroid hormones in the follow-up of differentiated thyroid cancer. The aim of the present study was to evaluate the influence of several demographic and anthropometric parameters [age, body weight, height, body mass index, and body surface area (BSA)] on serum peak TSH levels after rhTSH administration. rhTSH was administered to 112 patients with differentiated thyroid carcinoma according to the conventional two-dose schedule (0.9 mg/d). Serum TSH levels were measured 24 h before and after the first administration of rhTSH, and then 24, 48, and 72 h after the second administration of rhTSH. In one severely obese patient, serum peak TSH values did not reach a valid stimulation range. Serum peak TSH levels were negatively related to body weight (r = -0.69; P < 0.0001), body mass index (r = -0.51; P < 0.0001), and BSA (r = -0.72; P < 0.0001). In a multivariate regression analysis including demographic and anthropometric variables, only BSA was independently associated to serum peak TSH concentrations (standardized beta coefficient = -0.721; P < 0.0001). In conclusion, body size seems to influence serum peak TSH levels after rhTSH administration. Future studies should evaluate the possibility of using personalized rhTSH doses, adjusted in relation to BSA.
Vitale
Giovanni
G
Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica, Facoltà di Medicina e Chirurgia, Università degli Studi di Napoli Federico II, 80127 Napoli, Italy.
Lupoli
Gelsy Arianna
GA
Ciccarelli
Antonio
A
Lucariello
Antonio
A
Fittipaldi
Maria Rosa
MR
Fonderico
Francesco
F
Panico
Annalisa
A
Lupoli
Giovanni
G
D000293:Adolescent; D000328:Adult; D000368:Aged; D015992:Body Mass Index; D001830:Body Surface Area; D002648:Child; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000627:therapeutic use; D013964:Thyroid Neoplasms / Q000097:blood / Q000188:drug therapy*; D013972:Thyrotropin / Q000097:blood* / Q000627:therapeutic use*
D011994:Recombinant Proteins; D013972:Thyrotropin